Intravenous Immune Globulin (IVIG) Demonstration Ending on December 31, 2023

The Intravenous Immune Globulin (IVIG) Demonstration is ending on December 31, 2023. IVIG will become a permanent benefit of Medicare starting January 1, 2024. Suppliers should continue supplying IVIG as usual. The new fee schedule amount for IVIG in 2024 is $420.48. Suppliers will continue to bill with HCPCS code Q2052 (administration code). The Q2052 code and J codes (drug codes) can be billed on separate claims. Suppliers will need to bill the appropriate DME MAC based on the beneficiary’s permanent address with the Social Security Administration. For more information on these changes monitor our Website and Schedule of Events for webinars covering this information.

Last Updated $dateUtil.getDate( $modifieddate , "MMM dd , yyyy" , $locale , $tzone )